Genetic testing

Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage (genetic mother and father) through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans (e.g. to assess relatedness/ancestry or predict/diagnose genetic disorders), to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.

The variety of genetic tests has expanded throughout the years. Early forms of genetic testing which began in the 1950s involved counting the number of chromosomes per cell. Deviations from the expected number of chromosomes (46 in humans) could lead to a diagnosis of certain genetic conditions such as trisomy 21 (Down syndrome) or monosomy X (Turner syndrome). In the 1970s, a method to stain specific regions of chromosomes, called chromosome banding, was developed that allowed more detailed analysis of chromosome structure and diagnosis of genetic disorders that involved large structural rearrangements. In addition to analyzing whole chromosomes (cytogenetics), genetic testing has expanded to include the fields of molecular genetics and genomics which can identify changes at the level of individual genes, parts of genes, or even single nucleotide "letters" of DNA sequence. According to the National Institutes of Health, there are tests available for more than 2,000 genetic conditions, and one study estimated that as of 2018 there were more than 68,000 genetic tests on the market.

Limitations

The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or buccal smear (a procedure that samples cells from the inside surface of the cheek). The procedures used for prenatal testing carry a small but non-negligible risk of losing the pregnancy (miscarriage) because they require a sample of amniotic fluid or tissue from around the fetus.

Many of the risks associated with genetic testing involve the emotional, social, or financial consequences of the test results. People may feel angry, depressed, anxious, or guilty about their results. The potential negative impact of genetic testing has led to an increasing recognition of a "right not to know". In some cases, genetic testing creates tension within a family because the results can reveal information about other family members in addition to the person who is tested.

Genetic testing can provide only limited information about an inherited condition. The test often cannot determine if a person will show symptoms of a disorder, how severe the symptoms will be, or whether the disorder will progress over time. "A number of scientists and scholars said companies might not be fully explaining the limitations of genetic testing, or what results actually mean." Another major limitation is the lack of treatment strategies for many genetic disorders once they are diagnosed.

Another limitation to genetic testing for a hereditary linked cancer, is the variants of unknown clinical significance. Because the human genome has over 22,000 genes, there are 3.5 million variants in the average person's genome. These variants of unknown clinical significance mean there is a change in the DNA sequence, however the increase for cancer is unclear because it is unknown if the change affects the gene's function. A genetics professional can explain in detail the benefits, risks, and limitations of a particular test. It is important that any person who is considering genetic testing understands and weighs these factors before making a decision.

DNA studies have been criticised for a range of methodological problems and providing misleading interpretations on racial classifications.

Types

Genetic testing is "the analysis of chromosomes (DNA), proteins, and certain metabolites in order to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes." It can provide information about a person's genes and chromosomes throughout life.

From the date that a sample is taken, results may take weeks to months, depending upon the complexity and extent of the tests being performed. Results for prenatal testing are usually available more quickly because time is an important consideration in making decisions about a pregnancy. Prior to the testing, the doctor or genetic counselor who is requesting a particular test can provide specific information about the cost and time frame associated with that test.

Symptomatic diagnostic testing

  • Cell-free fetal DNA (cffDNA) testing – a non-invasive (for the fetus) test. It is performed on a sample of venous blood from the mother and can provide information about the fetus early in pregnancy. As of 2015 it is the most sensitive and specific screening test for Down syndrome.
Neonatal heel prick blood sample collection
  • Newborn screening – used just after birth to identify genetic disorders that can be treated early in life. A blood sample is collected with a heel prick from the newborn 24–48 hours after birth and sent to the lab for analysis. In the United States, newborn screening procedure varies state by state, but all states by law test for at least 21 disorders. If abnormal results are obtained, it does not necessarily mean the child has the disorder. Diagnostic tests must follow the initial screening to confirm the disease. The routine testing of infants for certain disorders is the most widespread use of genetic testing—millions of babies are tested each year in the United States. All states currently test infants for phenylketonuria (PKU, a genetic disorder that causes intellectual disability if left untreated) and congenital hypothyroidism (a disorder of the thyroid gland). People with PKU do not have an enzyme needed to process the amino acid phenylalanine, which is responsible for normal growth in children and normal protein use throughout their lifetime. If there is a buildup of too much phenylalanine, brain tissue can be damaged, causing developmental delay. Newborn screening can detect the presence of PKU, allowing children to be placed on special diets to avoid the effects of the disorder.
  • Diagnostic testing – used to diagnose or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on clinical features and symptoms. Diagnostic testing can be performed at any time during a person's life but is not available for all genes or all genetic conditions. The results of a diagnostic test can influence a person's choices about health care and the management of the disease. For example, people with a family history of polycystic kidney disease (PKD) who experience pain or tenderness in their abdomen, blood in their urine, frequent urination, pain in the sides, a urinary tract infection or kidney stones may decide to have their genes tested, and the result could confirm the diagnosis of PKD. Despite the several implications of genetic testing in conditions such as epilepsy or neurodevelopmental disorders, many patients (especially adults) do not have access to these modern diagnostic approaches, showing a relevant diagnostic gap.
  • Carrier testing – used to identify people who carry one copy of a gene mutation that, when present in two copies, causes a genetic disorder. This type of testing is offered to individuals who have a family history of a genetic disorder and to people in ethnic groups with an increased risk of specific genetic conditions. If both parents are tested, the test can provide information about a couple's risk of having a child with a genetic condition like cystic fibrosis.
  • Preimplantation genetic diagnosis – performed on human embryos prior to the implantation as part of an in vitro fertilization procedure. Pre-implantation testing is used when individuals try to conceive a child through in vitro fertilization. Eggs from the woman and sperm from the man are removed and fertilized outside the body to create multiple embryos. The embryos are individually screened for abnormalities, and the ones without abnormalities are implanted in the uterus.
Small amounts of the chorionic villi are sampled during CVS.
  • Prenatal diagnosis – used to detect changes in a fetus's genes or chromosomes before birth. This type of testing is offered to couples with an increased risk of having a baby with a genetic or chromosomal disorder. In some cases, prenatal testing can ease a couple's uncertainty or help them decide whether to abort the pregnancy. It cannot identify all possible inherited disorders and birth defects, however. One method of performing a prenatal genetic test involves an amniocentesis, which removes a sample of fluid from the mother's amniotic sac 15 to 20 or more weeks into pregnancy. The fluid is then tested for chromosomal abnormalities such as Down syndrome (trisomy 21) and trisomy 18, which can result in neonatal or fetal death. Test results can be retrieved within 7–14 days after the test is done. This method is 99.4% accurate at detecting and diagnosing fetal chromosome abnormalities. There is a slight risk of miscarriage with this test, about 1:400. Another method of prenatal testing is chorionic villus sampling (CVS). Chorionic villi are projections from the placenta that carry the same genetic makeup as the baby. During this method of prenatal testing, a sample of chorionic villi is removed from the placenta to be tested. This test is performed 10–13 weeks into pregnancy, and the results are ready 7–14 days after the test is done. Another test using blood taken from the fetal umbilical cord is percutaneous umbilical cord blood sampling.
  • Predictive and presymptomatic testing – used to detect gene mutations associated with disorders that appear after birth, often later in life. These tests can be helpful to people who have a family member with a genetic disorder but have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person's chances of developing disorders with a genetic basis, such as certain types of cancer. For example, an individual with a mutation in BRCA1 has a 65% cumulative risk of breast cancer. Hereditary breast cancer along with ovarian cancer syndrome are caused by gene alterations in the genes BRCA1 and BRCA2. Major cancer types related to mutations in these genes are female breast cancer, ovarian, prostate, pancreatic, and male breast cancer. Li-Fraumeni syndrome is caused by a gene alteration on the gene TP53. Cancer types associated with a mutation on this gene include breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia and brain tumors. In the Cowden syndrome there is a mutation on the PTEN gene, causing potential breast, thyroid or endometrial cancer. Presymptomatic testing can determine whether a person will develop a genetic disorder, such as hemochromatosis (an iron overload disorder), before any signs or symptoms appear. The results of predictive and presymptomatic testing can provide information about a person's risk of developing a specific disorder, help with making decisions about medical care and provide a better prognosis.
  • Pharmacogenomics – determines the influence of genetic variation on drug response. When a person has a disease or health condition, pharmacogenomics can examine an individual's genetic makeup to determine what medicine and what dosage would be the safest and most beneficial to the patient. In the human population, there are approximately 11 million single nucleotide polymorphisms (SNPs) in people's genomes, making them the most common variations in the human genome. SNPs reveal information about an individual's response to certain drugs. This type of genetic testing can be used for cancer patients undergoing chemotherapy. A sample of the cancer tissue can be sent in for genetic analysis by a specialized lab. After analysis, information retrieved can identify mutations in the tumor which can be used to determine the best treatment option.

Non-diagnostic testing

  • Forensic testing – uses DNA sequences to identify an individual for legal purposes. Unlike the tests described above, forensic testing is not used to detect gene mutations associated with disease. This type of testing can identify crime or catastrophe victims, rule out or implicate a crime suspect, or establish biological relationships between people (for example, paternity).
  • Paternity testing – uses special DNA markers to identify the same or similar inheritance patterns between related individuals. Based on the fact that we all inherit half of our DNA from the father, and half from the mother, DNA scientists test individuals to find the match of DNA sequences at some highly differential markers to draw the conclusion of relatedness.
  • Genealogical DNA test – used to determine ancestry or ethnic heritage for genetic genealogy.
  • Research testing – includes finding unknown genes, learning how genes work and advancing understanding of genetic conditions. The results of testing done as part of a research study are usually not available to patients or their healthcare providers.

Direct-to-consumer genetic testing

Direct-to-consumer (DTC) genetic testing (also called at-home genetic testing) is a type of genetic test that is accessible directly to the consumer without having to go through a health care professional. Usually, to obtain a genetic test, health care professionals such as physicians, nurse practitioners, or genetic counselors acquire their patient's permission and then order the desired test, which may or may not be covered by health insurance. DTC genetic tests, however, allow consumers to bypass this process and purchase DNA tests themselves. DTC genetic testing can entail primarily genealogical/ancestry-related information, health and trait-related information, or both. Genetic testing has been taken on by private companies, such as 23andMe, Ancestry.com, and Family Tree DNA. These companies will send the consumer a kit (such as Oragene) to their home address, with which they will provide a saliva sample for their lab to analyze. The company will then send back the consumer's results in a few weeks, providing a breakdown of their ancestral heritage and possible health risks that accompany it.

There are a variety of DTC genetic tests, ranging from tests for breast cancer alleles to mutations linked to cystic fibrosis. Possible benefits of DTC genetic testing are the accessibility of tests to consumers, promotion of proactive healthcare, and the privacy of genetic information. Possible additional risks of DTC genetic testing are the lack of governmental regulation, the potential misinterpretation of genetic information, issues related to testing minors, privacy of data, and downstream expenses for the public health care system. In the United States, most DTC genetic test kits are not reviewed by the Food and Drug Administration (FDA), with the exception of a few tests offered by the company 23andMe. As of 2019, the tests that have received marketing authorization by the FDA include 23andMe's genetic health risk reports for select variants of BRCA1/BRCA2, pharmacogenetic reports that test for selected variants associated with metabolism of certain pharmaceutical compounds, a carrier screening test for Bloom syndrome, and genetic health risk reports for a handful of other medical conditions, such as celiac disease and late-onset Alzheimer's.

Some advertising for DTC genetic testing has been criticized as conveying an exaggerated and inaccurate message about the connection between genetic information and disease risk, utilizing emotions as a selling factor. An advertisement for a BRCA-predictive genetic test for breast cancer stated: "There is no stronger antidote for fear than information." Apart from rare diseases that are directly caused by specific, single-gene mutation, diseases "have complicated, multiple genetic links that interact strongly with personal environment, lifestyle, and behavior." Critics of DTC genetic testing argue against the risks involved in several steps of the testing process, such as the unregulated advertising and marketing claims, the potential reselling of genetic data to third parties, the overall lack of governmental oversight, and inadequate pre-test information provision by DTC genetic testing sellers.

Marketing for ancestry tests often supports this misconception that humans can be separated into biologically distinct groups. However, genetic ancestry testing also has the potential to complicate these same notions. Subjectivities, based on identification with a particular race, can be challenged when genetic testing reveals ancestry from another group. For instance, someone who identifies as white may have their subjective experiences challenged upon discovering shared ancestry with a marginalised group. This can force them to examine ideas of what it means for them to continue identifying as white. Genetic ancestry tests impact on a person's subjective identification with race can even be mediated by their prior identifications. White consumers of these tests are more likely to identify with newly discovered ancestral backgrounds, due to viewing whiteness as boring or plain as opposed to the perceived exoticism of other identities.

Ethics

The possibility of genetic discrimination exists. Some individuals avoid genetic testing out of fear it will affect their ability to purchase insurance or find a job. Health insurers do not currently require applicants for coverage to undergo genetic testing, and when insurers encounter genetic information, it is subject to the same confidentiality protections as any other sensitive health information. In the United States, the use of genetic information is governed by the Genetic Information Nondiscrimination Act.

Incidental findings may be discovered while looking for something else. In 2013, the American College of Medical Genetics and Genomics (ACMG) recommended that certain genes always be included any time a genomic sequencing is done, and that labs should report the results.

Ancestry.com, a company providing DTC DNA tests for genealogy purposes, has reportedly allowed the warrantless search of their database by police investigating a murder. The warrantless search led to a search warrant to force the gathering of a DNA sample from a New Orleans filmmaker; however he turned out not to be a match for the suspected killer.

In Vitro Fertilisation

Ethical implications surrounding genetic testing also arise with the use of In Vitro Fertilisation (IVF). Genetic testing is used in IVF to test embryos for potentially fatal diseases to determine the strongest candidates. With this they are also able to see the sex of these embryos, meaning people who undergo IVF are able to choose the sex of their future child.

This gender selection of embryos is not aimed at assessing the viability of said embryo, rather a cultural act that has deep roots in most societies around the world. This practice perpetuates the historical gender power dynamics reflecting how gender and sex are central to kinship, inheritance, and cultural ideals of families. In patriarchal societies gender selection is used to facilitate son preference and the devaluing of daughters, reinforcing the existing hierarchies present in current society under the guise of choice.

This practice is justified under the context of reproductive autonomy, it is clear that these so-called choices are culturally informed and shaped by society. This reinforces the stereotypes of each gender's roles within a family unit. It is argued that technologies, such as these, sort embryos for socially desirable traits and removes the natural randomness of sex determination with targeted intervention.

Paediatric genetic testing

The American Academy of Pediatrics (AAP) and the American College of Medical Genetics (ACMG) have provided new guidelines for the ethical issue of pediatric genetic testing and screening of children in the United States. Their guidelines state that performing pediatric genetic testing should be in the best interest of the child. AAP and ACMG recommend holding off on genetic testing for late-onset conditions until adulthood, unless diagnosing genetic disorders during childhood can reduce morbidity or mortality (e.g., to start early intervention). Testing asymptomatic children who are at risk of childhood onset conditions can also be warranted. Both AAP and ACMG discourage the use of direct-to-consumer and home kit genetic tests because of concerns regarding the accuracy, interpretation and oversight of test content. Guidelines also state that parents or guardians should be encouraged to inform their child of the results from the genetic test if the minor is of appropriate age. For ethical and legal reasons, health care providers should be cautious in providing minors with predictive genetic testing without the involvement of parents or guardians. Within the guidelines set by AAP and ACMG, health care providers have an obligation to inform parents or guardians on the implication of test results. AAP and ACMG state that any type of predictive genetic testing should be offered with genetic counseling by clinical genetics, genetic counselors or health care providers.

Designer baby

Research

Three to five percent of the funding available for the Human Genome Project was set aside to study the many social, ethical, and legal implications that will result from the better understanding of human heredity and the rapid expansion of genetic risk assessment by genetic testing which would be facilitated by this project.

Biobank

The Genographic Project

In 2005, National Geographic launched the "Genographic Project", which was a fifteen-year project that was discontinued in 2020. Over one million people participated in the DNA sampling from more than 140 countries, making the project the largest of its kind ever conducted. The project asked for DNA samples from indigenous people as well as the general public, which spurred political controversy among some indigenous groups, leading to the coining of the term biocolonialism.

See also

References

  1. 1 2 "Genetic testing". American Medical Association. Retrieved October 3, 2019.
  2. ↑ "Paternity Testing". American Pregnancy Association. April 25, 2012. Retrieved October 3, 2019.
  3. ↑ Resnick B (January 28, 2019). "The limits of ancestry DNA tests, explained". Vox. Retrieved October 3, 2019.
  4. ↑ "UC Davis Veterinary Genetics Laboratory | Animal DNA testing | forensic testing | animal genetic research and diagnostics". vgl.ucdavis.edu. Retrieved October 3, 2019.
  5. ↑ "Selective breeding and gene technology". bbc.co.uk. Archived from the original on October 14, 2019. Retrieved October 14, 2019.
  6. ↑ Hunter ME, Hoban SM, Bruford MW, Segelbacher G, Bernatchez L (August 2018). "Next-generation conservation genetics and biodiversity monitoring". Evolutionary Applications. 11 (7): 1029–1034. Bibcode:2018EvApp..11.1029H. doi:10.1111/eva.12661. PMC 6050179. PMID 30026795.
  7. 1 2 Durmaz AA, Karaca E, Demkow U, Toruner G, Schoumans J, Cogulu O (2015). "Evolution of genetic techniques: past, present, and beyond". BioMed Research International. 2015 461524. doi:10.1155/2015/461524. PMC 4385642. PMID 25874212.
  8. ↑ "Karyotyping | Learn Science at Scitable". nature.com. Retrieved October 14, 2019.
  9. ↑ "NIH Fact Sheets - Genetic Testing: How it is Used for Healthcare". report.nih.gov. Archived from the original on August 16, 2019. Retrieved October 14, 2019.
  10. ↑ "10 New Genetic Tests Reach the Market Each Day". Medscape. Retrieved October 14, 2019.
  11. 1 2 3 "What are the risks and limitations of genetic testing?". Genetics Home Reference. Bethesda (MD): National Library of Medicine (US). November 15, 2016.
  12. ↑ Andorno R (October 2004). "The right not to know: an autonomy based approach". Journal of Medical Ethics. 30 (5): 435–439. doi:10.1136/jme.2002.001578. PMC 1733927. PMID 15467071.
  13. ↑ Wendelsdorf K (October 1, 2013). "You have a genetic disorder: Should your family be told they might carry the mutation?". Genetic Literacy Project.
  14. ↑ "Sulzberger, Arthur Hays, (12 Sept. 1891–11 Dec. 1968), Publisher of The New York Times, 1935–61; President of The New York Times Company, 1935–57; Director since 1935, and Chairman of the Board since 1957, of The New York Times Company, Interstate Broadcasting Company; Director and Chairman of the Board of the Times Printing Company (Chattanooga, Tennessee) since 1957; Chairman of the Chattanooga Publishing Company", Who Was Who, Oxford University Press, December 1, 2007, doi:10.1093/ww/9780199540884.013.u58392, retrieved December 2, 2025
  15. ↑ King E, Mahon SM (October 2017). "Genetic Testing: Challenges and Changes in Testing for Hereditary Cancer Syndromes". Clinical Journal of Oncology Nursing. 21 (5): 589–598. doi:10.1188/17.cjon.589-598. PMID 28945723. S2CID 7240065.
  16. ↑ Lieberman L, Jackson FL (1995). "Race and Three Models of Human Origin". American Anthropologist. 97 (2): 231–242. doi:10.1525/aa.1995.97.2.02a00030. ISSN 0002-7294. JSTOR 681958.
  17. ↑ Celenko T (1996). "The Geographical Origins and Population Relationships of Early Ancient Egyptians" In Egypt in Africa. Indianapolis, Ind.: Indianapolis Museum of Art. pp. 20–33. ISBN 0-936260-64-5.
  18. ↑ Brown RA, Armelagos GJ (2001). "Apportionment of racial diversity: A review". Evolutionary Anthropology. 10, Issue 1 (34–40): 34–40. doi:10.1002/1520-6505(2001)10:1<34::AID-EVAN1011>3.0.CO;2-P. S2CID 22845356.
  19. ↑ Eltis D, Bradley KR, Perry C, Engerman SL, Cartledge P, Richardson D (August 12, 2021). The Cambridge World History of Slavery. Vol. 2, AD 500-AD 1420. Cambridge University Press. p. 150. ISBN 978-0-521-84067-5.
  20. ↑ Candelora D, Ben-Marzouk N, Cooney K, eds. (August 31, 2022). Ancient Egyptian society: challenging assumptions, exploring approaches. Abingdon, Oxon: Taylor & Francis. pp. 101–122. ISBN 978-0-367-43463-2.
  21. ↑ Holtzman NA, Murphy PD, Watson MS, Barr PA (October 1997). "Predictive genetic testing: from basic research to clinical practice". Science. 278 (5338): 602–605. doi:10.1126/science.278.5338.602. PMID 9381169. S2CID 41939286.
  22. ↑ "What is the cost of genetic testing, and how long does it take to get the results?". Genetics Home Reference. Bethesda (MD): National Library of Medicine (US). November 15, 2016.
  23. ↑ Van den Veyver IB (October 28, 2016). "Recent advances in prenatal genetic screening and testing". F1000Research. 5: 2591. doi:10.12688/f1000research.9215.1. PMC 5089140. PMID 27853526.
  24. ↑ Permezel M, Walker S, Kyprianou K (2015). Beischer & MacKay's Obstetrics, Gynaecology and the Newborn. Elsevier Health Sciences. p. 74. ISBN 978-0-7295-8405-0. Retrieved January 24, 2017.
  25. 1 2 "Newborn Screening". Genetics Home Reference. Bethesda (MD): National Library of Medicine (US). Retrieved March 22, 2015.
  26. ↑ Mayo Clinic Staff. "Polycystic Kidney Disease". Mayo Clinic. Mayo Foundation for Medical Education and Research. Retrieved November 18, 2016.
  27. ↑ Aledo-Serrano A, García-Morales I, Toledano R, Jiménez-Huete A, Parejo B, Anciones C, et al. (October 2020). "Diagnostic gap in genetic epilepsies: A matter of age". Epilepsy & Behavior. 111 107266. doi:10.1016/j.yebeh.2020.107266. PMID 32610249. S2CID 220128591.
  28. ↑ Mayo Clinic Staff. "Genetic testing Why it's done - Tests and Procedures - Mayo Clinic". Mayo Clinic. Retrieved January 22, 2015.
  29. ↑ Haugen JA. "The Facts on Prenatal Testing". John A. Haugen Associates Obstetrics and Gynecology. Archived from the original on April 2, 2015. Retrieved March 26, 2015.
  30. ↑ Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. (May 2003). "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies". American Journal of Human Genetics. 72 (5): 1117–1130. Bibcode:2003AmJHG..72.1117A. doi:10.1086/375033. PMC 1180265. PMID 12677558.
  31. 1 2 "Genetic Testing for Hereditary Cancer Syndromes". National Cancer Institute. National Institute of Health. April 22, 2013. Retrieved November 18, 2016.
  32. ↑ "Genetic Testing". American Medical Association. Retrieved January 23, 2015.
  33. ↑ "Genomic Tumor Assessment". Cancer Treatment Centers for America. Rising Tide. Archived from the original on November 19, 2016. Retrieved November 18, 2016.
  34. ↑ "What is direct-to-consumer genetic testing?". Genetics Home Reference. Bethesda (MD): National Library of Medicine (US). Retrieved October 3, 2019.
  35. ↑ "At-home DNA test kits for 2022 | Medical News Today". medicalnewstoday.com. December 17, 2021. Retrieved November 9, 2022.
  36. ↑ Borry P, Cornel MC, Howard HC (September 2010). "Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market". Journal of Community Genetics. 1 (3): 101–106. doi:10.1007/s12687-010-0023-z. PMC 3063844. PMID 21475669.
  37. 1 2 "Direct-to-Consumer Tests". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. November 3, 2018. Archived from the original on June 14, 2019.
  38. ↑ Johnson CY. "23andMe gets FDA approval to report breast cancer risk without a doctor". Washington Post. Retrieved October 11, 2019.
  39. ↑ Gollust et al., "Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing," JAMA.2002; 288: 1762-1767
  40. ↑ Nisbet MC (2019). "DNA Is Not Destiny: Challenging the Hype over Genetic Testing". Skeptical Inquirer. Vol. 43, no. 4. pp. 28–30.
  41. ↑ Bruins D, Onstwedder S, Cornel M, Ausems M, van Mil M, Rigter T (April 20, 2024). "Information Provision Regarding Health-Related Direct-to-Consumer Genetic Testing for Dutch Consumers: An in-Depth Content Analysis of Sellers' Websites". Genes. 15 (4): 517. doi:10.3390/genes15040517. ISSN 2073-4425. PMC 11049909. PMID 38674451.
  42. ↑ Audeh MW (May 2008). "Letting the genome out of the bottle". The New England Journal of Medicine. 358 (20): 2184–5, author reply 2185. doi:10.1056/nejmc086053. PMID 18494080.
  43. ↑ Hunter DJ, Khoury MJ, Drazen JM (January 2008). "Letting the genome out of the bottle--will we get our wish?". The New England Journal of Medicine. 358 (2): 105–107. doi:10.1056/NEJMp0708162. PMID 18184955.
  44. ↑ Thiebes S, Toussaint PA, Ju J, Ahn JH, Lyytinen K, Sunyaev A (January 2020). "Valuable Genomes: Taxonomy and Archetypes of Business Models in Direct-to-Consumer Genetic Testing". Journal of Medical Internet Research. 22 (1) e14890. doi:10.2196/14890. PMC 7001042. PMID 31961329.
  45. ↑ Onstwedder SM, Jansen ME, Cornel MC, Rigter T (July 17, 2024). "Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study". Journal of Medical Internet Research. 26 e47389. doi:10.2196/47389. ISSN 1438-8871. PMC 11292153. PMID 39018558.
  46. 1 2 Benn T (2020). "Anthropological perspectives on genomic data, genetic ancestry, and race". American Journal of Physical Anthropology. 171 (70): 74–86. Bibcode:2020AJPA..171S..74B. doi:10.1002/ajpa.23979. PMID 31837009 – via WILEY Online Library.
  47. ↑ Roth, W, Ivemark, B. (2018). "Genetic options: The impact of genetic ancestry testing on consumers' racial and ethnic identities". American Journal of Sociology. 124 (1): 150–184. doi:10.1086/697487. JSTOR 26546171 – via JSTOR.
  48. ↑ Amy Harmon, "Insurance Fears Lead Many to Shun DNA Tests," The New York Times, February 24, 2008
  49. ↑ "Genetic Information and Medical Expense Insurance", American Academy of Actuaries, June 2000
  50. ↑ Wendelsdorf K (September 17, 2013). "Personal gene maps: Is there such a thing as too much information about our DNA?". Genetic Literacy Project.
  51. ↑ Powledge TM (March 24, 2015). "What should be done with unsettling 'incidental findings' in gene screens?". Genetic Literacy Project.
  52. ↑ Ronald Bailey, " Ancestry.com Hands Over Client DNA Test Results to Cops Without a Warrant" Reason.com
  53. ↑ Jim Mustian. "New Orleans filmmaker cleared in cold-case murder; false positive highlights limitations of familial DNA searching". The New Orleans Advocate. Archived from the original on July 11, 2016. Retrieved May 6, 2015.
  54. 1 2 Bumgarner A (2007). "A Right to Choose: Sex Selection in the International Context". Duke J. Gender L. & Pol'y. 14: 1289 – via Heinonline.
  55. ↑ Suryanarayanan S (June 1, 2025). Women's Empowerment and Son Preference in India: Feminist and Ethical discourse on Sex Selective Abortions. GB: Berghahn Books. ISBN 978-1-83695-008-0.
  56. ↑ Purewal N (2010). Son preference: Sex selection, gender, and culture in South Asia (1st ed.). United Kingdom: Bloomsbury Publishing (published April 2010). ISBN 978-1-84788-753-5.
  57. ↑ Ginsburg, Rapp, R. (1991). "The Politics of Reproduction". Annual Review of Anthropology. 20: 311–343. doi:10.1146/annurev.an.20.100191.001523. JSTOR 2155804. PMID 12288961 – via JSTOR.
  58. ↑ Franklin, S., Roberts, C. (October 30, 2006). Born and made: An ethnography of preimplantation genetic diagnosis. United States: Princeton University Press. ISBN 978-1-4008-3542-3.
  59. ↑ Rochman B (February 21, 2013). "New Guidelines for Genetic Testing in Children". Time.
  60. 1 2 Fallat ME, Katz AL, Mercurio MR, Moon MR, Okun AL, Webb SA, et al. (March 2013). "Ethical and policy issues in genetic testing and screening of children". Pediatrics. 131 (3): 620–622. doi:10.1542/peds.2012-3680. PMID 23428972. S2CID 42535260. All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time
  61. ↑ Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG (1994). Assessing Genetic Risks: Implications for Health and Social Policy. The National Academies Collection: Reports funded by National Institutes of Health. Institute of Medicine. ISBN 0-309-04798-6. PMID 25144102. Retrieved October 3, 2021.
  62. ↑ Duane J (June 2008). "Deep Ancestry: Inside the Genographic Project Wells Spencer . Deep Ancestry: Inside the Genographic Project. 2006. National Geographic Society. Washington, DC. $12.95, paperback. 247 pp. ISBN 13: 978-1426201189". Western North American Naturalist. 68 (2): 260–261. doi:10.3398/1527-0904(2008)68[260:daitgp]2.0.co;2. ISSN 1527-0904. S2CID 86171633.
  63. ↑ "Indigenous Peoples Council on Biocolonialism". ipcb.org. Retrieved November 9, 2022.

Sources